Published in Vaccine Weekly, September 22nd, 1997
Epimmune Inc. has been established to develop therapeutic and prophylactic products for cancer and infectious diseases. The Epimmune technology platform includes Cytel's library of proprietary antigenic epitopes, its proprietary Padre immunostimulant technology and its expertise in epitope discovery and immunology.
"Under the proposed collaboration, Epimmune and Searle intend to focus on the development of Epimmune's cancer technology which allows creation of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly